Table 1.
Main Clinical and Laboratory Characteristics of Individual Patients at Baseline.
| Characteristics | Case 1 | Case 2 | Case 3 |
|---|---|---|---|
| Age (years) | 24 | 73 | 37 |
| Gender (male/female) | male | male | male |
| Disease duration (months) | 4 | 6 | 150 |
| Clinical parameters | |||
| Body weight (kg) | 55.4 | 64.0 | 71.3 |
| Systolic blood pressure (mmHg) | 110 | 117 | 148 |
| Diastolic blood pressure (mmHg) | 58 | 77 | 92 |
| Laboratory parameters | |||
| Total protein (g/dL) | 4.0 | 4.0 | 4.4 |
| Serum albumin (g/dL) | 1.2 | 1.1 | 2.8 |
| Serum creatinine (mg/dL) | 0.69 | 3.59 | 2.38 |
| eGFR (mL/min/1.73m2) | 118.4 | 14.0 | 26.7 |
| Total cholesterol (mg/dL) | 259 | 369 | 246 |
| Urinary protein excretion (g/gCre) | 7.34 | 7.73 | 10.44 |
| anti-PLA2R antibody | negative | negative | positive |
| Treatment before rituximab | |||
| PSL (mg/day) | 25 | 20 | 5 |
| CyA (mg/day) | unused | 25 | unused |
| MMF (mg/day) | unused | unused | 1,000 |
| MZR (mg/day) | unused | 200 | unused |
| Former immunosuppressive drug | CyA, IVCY | nothing | CyA, MZR |
| RAS inhibitor agent | losartan 25mg | unused | unused |
eGFR: estimated glomerular filtration rate, Cre: creatinine, PLA2R: phospholipase A2 receptor, PSL: prednisolone, CyA: cyclosporine, IVCY: intravenous cyclophosphamide, MMF: mycophenolate mofetil, MZR: mizoribine, RAS: renin-angiotensin system